Investors Pump $257M Into Thrive’s Liquid Biopsy Test
Thrive is developing CancerSEEK, a liquid biopsy test designed to detect cancers at earlier stages of disease.
You may also be interested in...
AACR 2020: Liquid Biopsy Company Guardant Health Presents Colorectal Cancer Data, Outlines Plans For Regulatory Approval
Guardant Health presented new clinical data at this week’s American Association for Cancer Research conference and outlined its growth plans as cancer testing volumes recover after the pandemic.
The growth potential of liquid biopsy diagnostics is drawing increasing attention, with several recent breakthrough device designations from the US FDA, big funding rounds, and major acquisitions all in play.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.